You are here:
| Reference : Nuclear Factor-Kappa B, Cancer, and Apoptosis |
| Scientific journals : Article | |||
| Human health sciences : Oncology | |||
| http://hdl.handle.net/2268/18485 | |||
| Nuclear Factor-Kappa B, Cancer, and Apoptosis | |
| English | |
Bours, Vincent  [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine] | |
| Bentires-Alj, M. [> > > >] | |
| Hellin, A. C. [> > > >] | |
| Viatour, Patrick [Université de Liège - ULg > > Chimie médicale >] | |
| Robe, Pierre [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine >] | |
| Delhalle, S. [> > > >] | |
| Benoit, V. [> > > >] | |
| Merville, Marie-Paule [Université de Liège - ULg > Département de pharmacie > Chimie médicale >] | |
| 15-Oct-2000 | |
| Biochemical Pharmacology | |
| 60 | |
| 8 | |
| 1085-9 | |
| International | |
| 0006-2952 | |
| [en] The role of nuclear factor (NF)-kappa B in the regulation of apoptosis in normal and cancer cells has been extensively studied in recent years. Constitutive NF-kappa B activity in B lymphocytes as well as in Hodgkin's disease and breast cancer cells protects these cells against apoptosis. It has also been reported that NF-kappa B activation by tumor necrosis factor (TNF)-alpha, chemotherapeutic drugs, or ionizing radiations can protect several cell types against apoptosis, suggesting that NF-kappa B could participate in resistance to cancer treatment. These observations were explained by the regulation of antiapoptotic gene expression by NF-kappa B. However, in our experience, inhibition of NF-kappa B activity in several cancer cell lines has a very variable effect on cell mortality, depending on the cell type, the stimulus, and the level of NF-kappa B inhibition. Moreover, in some experimental systems, NF-kappa B activation is required for the onset of apoptosis. Therefore, it is likely that the NF-kappa B antiapoptotic role in response to chemotherapy is cell type- and signal-dependent and that the level of NF-kappa B inhibition is important. These issues will have to be carefully investigated before considering NF-kappa B as a target for genetic or pharmacological anticancer therapies. | |
| http://hdl.handle.net/2268/18485 |
There is no file associated with this reference.
All documents in ORBi are protected by a user license.
